Sugi Predict

Sugi Predict / Compounds / SCHEMBL308545

SCHEMBL308545

SCHEMBL308545

O=C(O)Cc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 9/20 0.57
▸ RXRB P28702 9/20 0.57
▸ RXRG P48443 9/20 0.57
▸ PSEN1 P49768 1/20 0.50
▸ PSEN2 P49810 1/20 0.50
▸ APH1B Q8WW43 1/20 0.50
▸ NCSTN Q92542 1/20 0.50
▸ APH1A Q96BI3 1/20 0.50
▸ PSENEN Q9NZ42 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.47
▸ RGS12 O14924 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ THPO P40225 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30120926 1.00 RXRA (0.57) RXRARXRBRXRGPSEN1PSEN2
SCHEMBL287631 0.86 RXRA (0.61) RXRARXRBRXRGPSEN1PSEN2
SCHEMBL12500917 0.85 RXRA (0.75) RXRARXRBRXRGPSEN1PSEN2
SCHEMBL4811433 0.84 NR3C2 (0.46) RXRARXRBRXRGNR3C2P2RX7
SCHEMBL12984838 0.84 NR3C2 (0.52) NR3C2P2RX7EPHX1PTPN7DUSP3
SCHEMBL6213644 0.84 P2RX7 (0.47) NR3C2P2RX7EPHX1PTPN7DUSP3
Hydrochloric Acid SCHEMBL1373105 0.84 RXRA (0.59) RXRARXRBRXRGPSEN1PSEN2
SCHEMBL1567847 0.83 NR3C2 (0.51) NR3C2
SCHEMBL30151151 0.83 NR3C2 (0.51) NR3C2
SCHEMBL12672486 0.81 P2RX7 (0.45) NR3C2P2RX7EPHX1PTPN7DUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051479-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CXCR3-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-02-13 — — US disclosed
US-20240382488-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-11-21 — — US disclosed
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2024-02-01 — — US disclosed
WO-2023161876-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CXCR3-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-31 — — WO disclosed
EP-4217065-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2023-08-02 — — EP disclosed
CN-116368112-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2023-06-30 — — CN disclosed
WO-2022212326-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-06 — — WO disclosed
CN-109053630-B Benzothiazole derivative and application thereof 中国人民解放军第二军医大学 2022-04-01 — — CN disclosed
WO-2022063767-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-03-31 — — WO disclosed
EP-2124562-B1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF SECOND GENOME INC (US) 2016-04-20 — — EP disclosed
US-6433188-B1 ANTIDIABETIC AGENTS CORBETT WENDY LEA (US) 2002-08-13 — — US disclosed
US-20020107396-A1 FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS CORBETT WENDY LEA (US) 2002-08-08 — — US disclosed
US-20020103199-A1 Fused heteroaromatic glucokinase activators CORBETT WENDY LEA (US) 2002-08-01 — — US disclosed
US-20020103241-A1 FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS CORBETT WENDY L (US) 2002-08-01 — — US disclosed
WO-2002046173-A1 FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-06-13 — — WO disclosed
CN-1349519-A Glucokinase activators HOFFMANN LA ROCHE (CH) 2002-05-15 — — CN disclosed
EP-1169312-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-09 — — EP disclosed
US-6320050-B1 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. HOFFMANN-LA ROCHE INC. 2001-11-20 — — US disclosed
US-20010039344-A1 Heteroaromatic glucokinase activators HOFFMANN-LA ROCHE INC. 2001-11-08 — — US disclosed
WO-2000058293-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103199-A1 Fused heteroaromatic glucokinase activators GCKR, GCK, GPR119 RXRA 3180/4885RXRB 3210/4885RXRG 2834/4885
US-20240382488-A1 NEK7 INHIBITORS NEK7, NEK11, NEK2 RXRA 2874/4885RXRB 3018/4885RXRG 2180/4885
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 RXRA 3050/4885RXRB 2691/4885RXRG 2663/4885
US-20020107396-A1 FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS GCKR, GCK, GPR119 RXRA 3180/4885RXRB 3210/4885RXRG 2834/4885
US-20010039344-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK RXRA 3137/4885RXRB 3419/4885RXRG 3082/4885
US-20020103241-A1 FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS GCKR, GCK, GPR119 RXRA 3180/4885RXRB 3210/4885RXRG 2834/4885
US-20250051479-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CXCR3-EXPRESSING CELLS CXCR3, CXCL10, CCR5 RXRA 916/4885RXRB 787/4885RXRG 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.